瑞舒伐他汀对代谢综合征患者血清血管生成素2和炎症因子水平的影响

Influence of Rosuvastatin on Serum Ang-2 and Inflammatory Factors in Patients with Metabolic Syndrome

目的观察瑞舒伐他汀对代谢综合征(MS)患者血清血管生成素2(Ang-2)和炎症因子水平的影响及其安全性。方法将80例MS患者分为治疗组(40例)和对照组(40例),两组均给予降压治疗,同时治疗组加用瑞舒伐他汀10 mg/d,对照组不用任何调脂药。治疗前和治疗8周后分别检测血清Ang-2、肿瘤坏死因子(TNF-α)、白介素6(IL-6)、白介素18(IL-18)、空腹胰岛素(FINS)、空腹血糖(FPG)水平及肝、肾功能,比较两组治疗前、后各指标的差异。结果 (1)治疗8周后,治疗组患者的Ang-2、TNF-α、IL-6、IL-18、FINS水平及胰岛素抵抗指数(HOMA-IR)均较本组治疗前及对照组治疗后显著降低,差异均有统计学意义(P<0.05);而对照组各指标在治疗前后比较差异均无统计学意义(P>0.05)。(2)治疗组治疗期间有5例有短暂的胃肠道反应,3例肌酸磷酸激酶(CK)轻度升高,均未停药及特殊处理。结论瑞舒伐他汀可降低MS患者Ang-2和炎症因子水平,改善胰岛素抵抗,且安全性良好。

Objective To observe the influence and safety of rosuvastatin on serum Ang-2 and inflammatory factors in patients with metabolic syndrome（MS）.Methods 80 MS patients were divided into treatment group（40 cases） and control group（40 cases）.The two groups were both given antihypertensive treatment.The treatment group was also given rosuvastatin by 10 mg/d,while the control group was not given any lipid-lowering drugs.The levels of Ang-2,TNF-α,IL-6,IL-18,FINS,FPG and liver and kidney functions were measured before treatment and eight weeks after treatment.The indexes of the two groups before and after treatment were compared.Results（1） After eight weeks treatment,the levels of Ang-2,TNF-α,IL-6,IL-18,FINS and HOMA-IR in treatment group were significantly lower than those before treatment in this group and those after treatment in control group（P〈0.05）.The above indexes showed no statistically significant differences before and after treatment in control group（P〉0.05）.（2）Five cases in treatment group had short-term gastrointestinal side effects in the course of treatment,and three cases had mild increase of creatine kinase（CK）,but no drug withdrawal or special treatment were given.Conclusion Rosuvastatin can reduce the levels of serum Ang-2 and inflammatory factors and improve insulin resistance in patients with MS with good safety.